Quarterly results
2019 Second quarter
We will announce our second quarter 2019 results at 12:00 BST, 07:00 EDT on Wednesday 24 July.
Following the announcement there will be a webcast, hosted by Emma Walmsley, CEO; Iain Mackay, CFO; and Hal Barron, Chief Scientific Officer and President, R&D at 14:00 BST, 09:00 EDT.
-
2011 Fourth Quarter - released 07 February 2012
Sir Andrew Witty, CEO, discusses our fourth quarter results 2011.
Key highlights
- 2011 underlying sales +4% (reported -3%)
- EPS before major restructuring* 114.1p
- Total dividends of 75p
Related downloads
- Q4 2011 results announcement PDF - 331.1KB
- Q4 2011 Andrew Witty video transcript PDF - 104.1KB
- Q4 2011 Simon Dingemans video transcript PDF - 27.7KB
- Q4 2011 analyst presentation PDF - 1.8MB
- Q4 2011 restated quarterly product analysis PDF - 96.8KB
- Q4 2011 actual growth schedules PDF - 47.4KB
- Q4 2011 US dollar translation PDF - 45.1KB
-
2011 Third Quarter - released 26 October 2011
Simon Dingemans, CFO, discusses our third quarter results 2011.
Key highlights
- Underlying sales growth of 6% and reported sales growth of 3%
- EPS before major restructuring 28.5p, dividend 17p (up 6%)
- Strong contribution from Japan: sales +57%
-
2011 Second Quarter - released 26 July 2011
Andrew Witty, CEO, and Simon Dingemans, CFO, discuss our second quarter results 2011.
Key highlights
- Q2 reported sales -2%
- EPS before major restructuring* 25p
- Underlying sales growth of 5%
- Increased pipeline visibility and dividend of 16p, up 7%
-
2011 First Quarter - released 27 April 2011
Andrew Witty, CEO, discusses our first quarter results 2011.
Key highlights
- Reported sales -10%, underlying sales +4%
- EPS before major restructuring 32.2p (+9%), dividend 16p (+7%)
Other key information
-
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
-
Press releases
Keep up to date with our news and recent announcements
-
Corporate Executive Team
The Corporate Executive Team manages our activities, and each member is responsible for a specific part of the business
-
Our pipeline
We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients and payers.
